JNJ Johnson & Johnson

127.7
-8.47  -6%
Previous Close 136.17
Open 133.31
Price To Book 5.54
Market Cap 337,021,437,798
Shares 2,639,165,527
Volume 25,873,942
Short Ratio 2.66
Av. Daily Volume 7,732,818
Stock charts supplied by TradingView

NewsSee all news

  1. Johnson & Johnson Reports 2019 Third-Quarter Results

    NEW BRUNSWICK, N.J., Oct. 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for third-quarter 2019. "Our third-quarter results represent strong performance, driven by competitive

  2. Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review

    NEW BRUNSWICK, N.J., Oct. 7, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review

  3. Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis

    NEW BRUNSWICK, N.J., Oct. 4, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery

  4. Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial

    NEW BRUNSWICK, N.J., Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that

  5. California Jury Returns $40 Million Talc Verdict Against Johnson & Johnson

    LOS ANGELES, Sept. 30, 2019 /PRNewswire/ -- A California woman suffering from mesothelioma has prevailed in the latest talc trial against Johnson & Johnson, following six days of jury deliberation that ended Friday

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Phase 3 discontinuation announced October 17, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Approval announced February 14, 2018.
Apalutamide
Non-metastatic castration-resistant prostate cancer (CRPC)
FDA Approval announced July 17, 2018.
D/C/F/TAF
HIV
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
FDA approval announced October 14, 2019.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
FDA Approval announced October 30, 2018.
INVOKANA CANVAS
Type 2 diabetes
FDA Approval announced September 30, 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Approval announced May 7, 2018.
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
FDA approval announced March 5, 2019.
Esketamine
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced October 13, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approval announced October 20, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approval announced October 20, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
Approval announced July 13, 2017.
Guselkumab
Plaque psoriasis
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Sirukumab
Rheumatoid arthritis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
sNDA approval announced February 8, 2018.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
FDA Approval announced April 12, 2019.
Erdafitinib
Urothelial cancer
NDA filing announced April 29, 2019. Estimated PDUFA date April 28, 2020.
Dolutegravir + rilpivirine
Injectable 2DR in HIV
Announced May 18, 2018 that dosing will be stopped.
Atabecestat
Alzheimer’s disease
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
FDA Approval announced June 28, 2019.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Phase 2a initiation announced January 17, 2019.
Guselkumab
Ulcerative colitis
sBLA filed December 20, 2018. Estimated PDUFA date December 19, 2019.
STELARA (USTEKINUMAB)
Ulcerative colitis
FDA Approval announced September 18, 2019.
Apalutamide
Metastatic castration-sensitive prostate cancer (mCSPC).
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer
Approval announced February 27, 2019.
Guselkumab
Plaque psoriasis
FDA Approval announced September 26, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Phase 3 trial met primary endpoint.
Ponesimod
Relapsing multiple sclerosis
sBLA filing announced September 16, 2019.
Guselkumab
Psoriatic Arthritis
sNDA filing announced October 2, 2019.
Esketamine
Major depressive disorder (MDD)
sBLA filing announced October 7, 2019.
STELARA (USTEKINUMAB)
Plaque psoriasis - pediatric

Latest News

  1. Johnson & Johnson Reports 2019 Third-Quarter Results

    NEW BRUNSWICK, N.J., Oct. 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for third-quarter 2019. "Our third-quarter results represent strong performance, driven by competitive

  2. Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review

    NEW BRUNSWICK, N.J., Oct. 7, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review

  3. Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis

    NEW BRUNSWICK, N.J., Oct. 4, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery

  4. Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial

    NEW BRUNSWICK, N.J., Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that

  5. California Jury Returns $40 Million Talc Verdict Against Johnson & Johnson

    LOS ANGELES, Sept. 30, 2019 /PRNewswire/ -- A California woman suffering from mesothelioma has prevailed in the latest talc trial against Johnson & Johnson, following six days of jury deliberation that ended Friday

  6. Johnson & Johnson Vision Care, Inc. Introduces ACUVUE™ RevitaLens Multi-Purpose Disinfecting Solution, the Brand's First Contact Lens Solution

    JACKSONVILLE, Fla., Sept. 30, 2019 /PRNewswire/ -- Johnson & Johnson Vision† is excited to unveil the first-ever extension of the ACUVUE® brand name beyond contact lenses with today's launch of ACUVUE™ RevitaLens

  7. Johnson & Johnson to Host Investor Conference Call on Third Quarter Results

    NEW BRUNSWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th to review third-quarter results.  Joseph

  8. Thinking about trading options or stock in Apple, Goldman Sachs, Johnson & Johnson, Microsoft, or Tesla?

    NEW YORK, Sept. 6, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, GS, JNJ, MSFT, and TSLA. Click a link below then choose between in-depth options trade idea report or a stock score

  9. Johnson & Johnson to Participate in the 2019 Morgan Stanley 17th Annual Global Healthcare Conference

    NEW BRUNSWICK, N.J., Aug. 29, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) will participate in the 2019 Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th, at The Grand Hyatt

  10. Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma

    Johnson & Johnson (NYSE:JNJ) and its Janssen Pharmaceutical Companies announced they will appeal the $572 million civil judgment entered in Cleveland County District Court in the State of Oklahoma's lawsuit

  11. Thinking about trading options or stock in Apple, Salesforce, Facebook, Johnson & Johnson, or Tyson Foods?

    NEW YORK, Aug. 27, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CRM, FB, JNJ, and TSN. Click a link below then choose between in-depth options trade idea report or a stock score

  12. Everyday Health Group Acquires BabyCenter, the Leading Global Digital Parenting Resource

    Everyday Health Group, a division of J2 Global, Inc. (NASDAQ:JCOM), announced today that it has acquired BabyCenter, the leading global digital pregnancy and parenting resource, from Johnson & Johnson

  13. Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma

    NEW BRUNSWICK, N.J., Aug. 26, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) and its Janssen Pharmaceutical Companies today announced they will appeal the $572 million civil judgment entered in Cleveland County